• Channels
    • All News
    • Premium Content
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Law
    • Manufacturing
    • Marketing
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Bio­gen’s Covid-19 tal­ly breaks past the 100 mark, feed­ing the state to­tal as the con­ta­gion wreaks hav­oc

3 years ago
Coronavirus

Biotech en­tre­pre­neurs Arie Bellde­grun and Cedric Fran­cois test pos­i­tive for Covid-19 — and here's why they want you to know

3 years ago
People
Coronavirus

The E100 biotech sur­vey: Ex­ecs are hun­ker­ing down for the pan­dem­ic, wor­ried about longterm fall­out — but ea­ger to see bio­phar­ma make a dif­fer­ence

3 years ago
Special

FDA of­fers Roche an emer­gency OK for coro­n­avirus test­ing tech — eas­ing a crit­i­cal log­jam

3 years ago
FDA+
Coronavirus

Bio­gen out­break con­tin­ues to spur new coro­n­avirus cas­es in Mass­a­chu­setts as health of­fi­cials strug­gle to keep up with test­ing de­mands

3 years ago
R&D
Coronavirus

A one-time biotech uni­corn gets slaugh­tered as lead pro­gram is scrapped, high­light­ing lin­ger­ing trou­ble

3 years ago
R&D
FDA+

Vir’s George Scan­gos teams up with his for­mer col­leagues at Bio­gen to press fast-for­ward on an­ti­body pro­grams for coro­n­avirus

3 years ago
People
R&D

Flag­ship merges two star­tups to build a $220M Reper­toire of T cell tech, ther­a­pies

3 years ago
Deals

Af­ter a year of big ad­vances, As­traZeneca CEO Pas­cal So­ri­ot takes home a ma­jor-league pay pack­age

3 years ago
People
Deals

Dis­ap­point­ing PhI­II re­sults dash As­traZeneca's hopes of re­viv­ing a tar­nished can­cer drug through Lyn­parza com­bo

3 years ago
R&D

As the coro­n­avirus pan­dem­ic con­tin­ues to rat­tle the world, bio­phar­ma braces for a few new shocks to the sys­tem

3 years ago
Coronavirus

A JP Mor­gan promise, a last-minute bid and the coro­n­avirus stock mar­ket — how Gilead’s Daniel O’Day nabbed Forty Sev­en

3 years ago
Deals
R&D

An­a­lysts start to sort out which bio­phar­ma com­pa­nies’ R&D plans are most threat­ened by a pan­dem­ic

3 years ago
R&D
Coronavirus

Af­ter hit­ting big in mul­ti­ple myelo­ma, J&J, Gen­mab now have a new 'break­through' in NSCLC to boast about

3 years ago
FDA+

Bio­gen out­break now tied to 70 cas­es of coro­n­avirus as state to­tal more than dou­bles in 1 day

3 years ago
Coronavirus

Coro­n­avirus up­date: Eli Lil­ly staffer tests pos­i­tive, FDA post­pones in­spec­tions and AACR is can­celed as out­break roils bio­phar­ma

3 years ago
Coronavirus

Which top-lev­el Bio­gen ex­ec has test­ed pos­i­tive for coro­n­avirus? WSJ nar­rows the lot­tery to 4, in­clud­ing the CEO

3 years ago
Coronavirus

Gates Foun­da­tion, Mas­ter­card, Well­come launch coro­n­avirus treat­ment ac­cel­er­a­tor as out­break deep­ens

3 years ago
Coronavirus

Bris­tol My­ers backs a Eu­ro­pean VC's record-set­ting biotech ven­ture fund, which tops out at $600M

3 years ago
R&D
Pharma

Nine new coro­n­avirus cas­es are tied to the Bio­gen out­break — as in­fec­tions spread to 'close con­tact­s'

3 years ago
People
Pharma

ACC scraps its flag­ship event in Chica­go as Covid-19 fears spread faster than the virus

3 years ago
Coronavirus

Bio­phar­ma stocks take a beat­ing as eco­nom­ic tur­moil takes its toll — but some play­ers with coro­n­avirus ef­forts un­der­way are up

3 years ago
Coronavirus

As Bio­gen grap­ples with coro­n­avirus cri­sis, Big Phar­mas like Eli Lil­ly, Take­da hun­ker down, tell staffers to work from home

3 years ago
Pharma
Coronavirus

Tal­ly of coro­n­avirus cas­es at Bio­gen spikes by 15 on Sun­day — and Cowen says one in­fect­ed ex­ec at­tend­ed big con­fer­ence

3 years ago
Coronavirus
First page Previous page 116117118119120121122 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Content
  • Don't Miss
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Law
  • Manufacturing
  • Marketing
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints Company 2022

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
Endpoints News

Log in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET